Katana engineers immune-evasive, armored cell therapies from induced pluripotent stem cells.
Shinobi Therapeutics
Shinobi Therapeutics, a California-based biotech firm, innovates immune-evasive cell treatments.
Shinobi Therapeutics, a California-based biotech firm, innovates immune-evasive cell treatments.
Shinobi Therapeutics, founded in South San Francisco, California, is a pioneering biotechnology company focused on developing immune-evasive induced pluripotent stem cell (iPSC) therapies. Their core mission is to harness the potential of iPSCs to create treatments that can effectively work with the immune system rather than against it, aiming to cure cancer and other severe diseases. Shinobi Therapeutics offers a novel class of cell treatments designed to evade the immune system, addressing a critical barrier in current cell therapy approaches.
Notable affiliated individuals and investors include those involved in their recent successful $51 million Series A funding round. This significant financial backing underscores the confidence in their innovative approach and potential impact. Shinobi Therapeutics has made key advancements in immune evasion technology, positioning itself as a leader in the biotech field. Their work promises to revolutionize the treatment landscape for numerous debilitating conditions, potentially offering new hope to patients worldwide.
Companies similar to Shinobi Therapeutics include Khloris Biosciences, Shoreline Biosciences, Cellevolve Bio and Refuge Biotechnologies.
Shinobi Therapeutics was founded in 2023.
Shinobi Therapeutics' headquarters is located in South San Francisco, CA, US.
Shinobi Therapeutics' most recent funding round was for $51M (USD) in December 2023.
As of Dec 12, 2023, Shinobi Therapeutics has disclosed funding of $51M (USD). Undisclosed round amounts are excluded.
Shinobi Therapeutics has 30 employees as of Feb 4, 2024.
Refuge Biotechnologies
